Back

Thiazides attenuate the diuretic response to pecavaptan, a dual vasopressin receptor antagonist, in hospitalized heart failure patients

9 May 2026 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Navigating the cardio-renal syndrome (2) Pharmacotherapy Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Mr Daan Ceelen

University Medical Centre Groningen, Groningen (Netherlands (The))

5 More presentations in this session

Presentation thumbnail
Renal and electrolyte safety of acetazolamide Add-On decongestion in heart failure: a systematic review
Doctor R. Ali (Pembroke Pines, US)
Abstract
Presentation thumbnail
Predicting diuretic resistance without urine output in acute heart failure
Mrs E. Vice (Atlanta, US)
Abstract
Presentation thumbnail
Renal safety of a natriuresis-guided diuretic strategy in hospitalised heart failure
Doctor S. Singh (Hartford, US)
Abstract
Presentation thumbnail
Sustained low-efficiency dialysis for refractory congestion in advanced cardiorenal syndrome: haemodyamics and weight reduction analysis
Doctor G. Mihelcic (London, GB)
Abstract
Presentation thumbnail
Hyperkalemia incidence and recurrence among patients with heart failure - predictors and temporal trends
Doctor F. Lindberg (Stockholm, SE)
Abstract

Access the full session

Session thumbnail
Navigating the cardio-renal syndrome (2)

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026
You may be interested in
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios
thumbnail
Congress Presentation
Audience Q&A
thumbnail
Congress Presentation
Did we forget ARNI in the era of SGLTi?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources